CLAIMS

1. A diarylamide derivative represented by general formula (1) or a pharmaceutically acceptable salt thereof:

$$R^{5}$$
 R^{4}
 R^{3}
 R^{2}
 R^{2}
 R^{1}
 R^{1}
 R^{1}
 R^{2}
 R^{3}
 R^{2}
 R^{3}
 R^{2}
 R^{3}
 R^{2}
 R^{3}
 R^{2}

wherein,

A is an aromatic ring selected from the group consisting of a benzene ring, a pyridine ring, a thiophene ring, a furan ring, and a naphthalene ring;

a substituent represented by COY and a substituent represented by NHCOX are adjacent to each other and these substituents are linked to a carbon atom in the aromatic ring;

X denotes a C_1 - C_4 -alkylene group, a C_1 - C_4 -alkyleneoxy group, or a single bond;

Y is selected from the group consisting of a C_1 - C_4 -alkyl group, a C_1 - C_4 -alkoxy group, a hydroxyl group, and $N(R^6)(R^7)$ in which each of R^6 and R^7 , which can be the same or different, is selected from the group consisting of a hydrogen atom, a C_1 - C_4 -alkyl group, a C_1 - C_4 -alkoxy group, a C_3 - C_9 -cycloalkyl group, a C_4 - C_9 -cycloalkyl-alkyl group, a C_5 - C_8 -morpholino-N-alkoxy group, a C_3 - C_9 -alkenyl group, a phenyl group, a pyridyl group, and an aralkyl group, wherein the phenyl group and the pyridyl group and the aromatic ring of the aralkyl group are optionally substituted with 1 to 3 substituents selected from the group consisting of a C_1 - C_4 -alkyl group, a C_1 - C_4 -alkoxy group, and a halogen atom;

 R^1 is selected from the group consisting of a hydrogen atom, a halogen atom, a hydroxyl group, a C_1 - C_4 -alkyl group, a C_3 - C_9 -cycloalkyl group, a C_4 - C_9 -cycloalkylalkyl group, a C_1 - C_4 -alkoxy group, a C_3 - C_9 -cycloalkyloxy group, a C_4 - C_9 -cycloalkylalkoxy group, an aralkyloxy group, a C_1 - C_4 -acyl group, and a nitro group and 1 to 4 R^1 s are present at a desired position in A, each of which can be the same or different, and

when two R^1 s are present, they may together form a C_1 - C_4 -alkylenedioxy group, provided that, when A is a benzene ring, R^1 does not denote a hydrogen atom;

B denotes a benzene, pyridine, or thiophene ring;

 R^2 is a substituent selected from the group consisting of a hydrogen atom, a halogen atom, a hydroxyl group, a C_1 - C_4 -alkyl group, a C_1 - C_4 -alkoxy group, a C_1 - C_4 -hydroxyalkoxy group, a C_3 - C_9 -cycloalkyloxy group, a C_4 - C_9 -cycloalkyl-alkoxy group, an aralkyloxy group, a C_1 - C_4 -acyl group, a cyano group, a C_5 - C_8 -morpholino-N-alkoxy group, and an amino group which can be monosubstituted or disubstituted with a C_1 - C_4 -alkyl group, and 1 to 4 R^2 s, each of which can be the same or different, are present at a desired position;

R³ and R⁴ denote, when Y denotes other than a C₁-C₄-alkyl group, an oxygen atom or NR⁸ in which each R⁸ is selected from the group consisting of a hydrogen atom and a C₁-C₄-alkyl group, each of which can be the same or different, and when Y denotes a C₁-C₄-alkyl group, R³ denotes an oxygen atom or NR⁸ and R⁴ denotes an oxygen atom, NR⁸, or a single bond;

R⁵ is selected from the group consisting of a C₁-C₈-alkyl group, a C₂-C₄-alkenyl group, a C₃-C₉-cycloalkyl group, a C₄-C₉-cycloalkyl-alkyl group, a tetrahydropyranyl group, an aralkyl group, an indanyl group, an aromatic acyl group, a phenyl group, a pyridyl group, a furyl group, and a thienyl group wherein the aromatic rings of the aralkyl group, the indanyl group, and the aromatic acyl group, the phenyl group, the pyridyl group, the furyl group, and the thienyl group optionally have 1 to 5 substituents selected from the group consisting of a halogen atom, a hydroxyl group, a cyano group, a C₁-C₄-alkyl group, a C₁-C₄-alkoxy group, a C₁-C₄-alkylthio group, a C₂-C₅-alkoxycarbonyl group, a carboxyl group, a C₁-C₄-acyl group, an aromatic acyl group, a C₁-C₄-acyloxy group, a trifluoromethyl group, a phenyl group, a phenoxy group, a phenylthio group, a pyridyl group, a morpholino group, an aralkyloxy group, a nitro group, a methylsulfonyl group, an aminosulfonyl group, and an amino group that is optionally monosubstituted or disubstituted with a C₁-C₄-alkyl group or a C₁-C₄-acyl group, and wherein adjacent two substituents may together form a C₁-C₄-alkylenedioxy group to form a ring; and

Z denotes an oxygen or sulfur atom.

- 2. The compound according to claim 1 wherein, in general formula (1), X denotes a C_1 - C_4 -alkylene group.
 - 3. The compound according to claim 1 wherein, in general formula (1), X

denotes a single bond.

- 4. The compound according to claim 1 wherein, in general formula (1), each of A and B, which can be the same or different, denotes a benzene ring or a pyridine ring.
- 5. The compound according to claim 1 wherein, in general formula (1), A and B denote a benzene ring.
- 6. The compound according to claim 1 wherein, in general formula (1), Y denotes an unsubstituted amino group, a hydroxyl group, or a C_1 - C_4 -alkoxy group.
- 7. The compound according to claim 1 wherein, in general formula (1), Y denotes a C_1 - C_4 -alkyl group.
- 8. The compound according to claim 1 wherein, in general formula (1), R^2 denotes a hydrogen atom or a C_1 - C_4 -alkoxy group.
- 9. The compound according to claim 1 wherein, in general formula (1), R⁵ denotes a benzyl group, a phenyl group, a pyridyl group, or a pyridylmethyl group wherein the aromatic rings of the benzyl group and the pyridylmethyl group and the phenyl group and the pyridyl group optionally have 1 to 5 substituents selected from the group consisting of a halogen atom, a C₁-C₄-alkyl group, a C₁-C₄-alkoxy group, a C₂-C₅-alkoxycarbonyl group, a C₁-C₄-acyl group, a trifluoromethyl group, a C₁-C₄-alkyl group, and an amino group which has been disubstituted with a C₁-C₄-alkyl group.
- 10. The compound according to claim 1 wherein, in general formula (1), R^5 denotes a C_1 - C_4 -alkyl group, a C_2 - C_4 -alkenyl group, or a C_3 - C_6 -cycloalkyl group.
- 11. The compound according to claim 1 wherein, in general formula (1), R^3 and R^4 denote NH.
- 12. The compound according to claim 1 wherein, in general formula (1), R^3 denotes NH and R^4 denotes an oxygen atom.
 - 13. A pharmaceutical composition comprising, as an active ingredient, the

compound or pharmaceutically acceptable salt thereof according to claim 1.

- 14. A pharmaceutical composition comprising, as an active ingredient, the compound or pharmaceutically acceptable salt thereof according to claim_1, that is usable for prevention or treatment of diseases caused by abnormal proliferation of vascular smooth muscle cells.
- 15. A pharmaceutical composition comprising, as an active ingredient, the compound or pharmaceutically acceptable salt thereof according to claim 1, that is usable for prevention or treatment of restenosis or atherosclerosis after percutaneous transluminal coronary angioplasty or coronary artery bypass surgery.
- 16. A pharmaceutical composition comprising, as an active ingredient, the compound or pharmaceutically acceptable salt thereof according to claim 1, that is usable for prevention or treatment of diseases caused by abnormal proliferation of mesangial cells.
- 17. A pharmaceutical composition comprising, as an active ingredient, the compound or pharmaceutically acceptable salt thereof according to claim 1, that is usable for prevention or treatment of diseases caused by abnormal proliferation of vascular endothelial cells or epidermal cells.
- 18. A pharmaceutical composition comprising, as an active ingredient, the compound or pharmaceutically acceptable salt thereof according to claim 1, that is usable for prevention or treatment of psoriasis, diabetic retinopathy, or senile disciform macular degeneration.